# FANCA

Source: https://onco.cc/targets/fanca/  
OnCo record `fanca` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.

## Summary

DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Cisplatin. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes genetic literature 0.83, affected pathway 0.67, literature 0.95, genetic association 0.58, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Prostate Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FA complementation group A; Fanconi anemia group A protein; FA-H; FANCH
- Tags: cancer-genes-wave
- Symbol: FANCA
- Class: oncogene
- Biology: DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Location: Nucleus; Cytoplasm (UniProt). Locus 16q24.3 (HGNC).
- Where found: Leukaemia: Open Targets association 0.64 with leukaemia (MONDO_0005059); Skin cancer: Open Targets association 0.61 with skin cancer (MONDO_0002898); Ovarian cancer: Open Targets association 0.60 with ovarian cancer (MONDO_0008170); Prostate cancer: Open Targets association 0.52 with prostate cancer (MONDO_0008315); CIViC evidence names this disease; Myeloproliferative neoplasms: Open Targets association 0.56 with myeloproliferative neoplasm (MONDO_0020076); Lung cancer: Open Targets association 0.52 with lung cancer (MONDO_0008903)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3582: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3582
- UniProt O15360: https://www.uniprot.org/uniprotkb/O15360/entry
- NCBI Gene 2175: https://www.ncbi.nlm.nih.gov/gene/2175
- Ensembl ENSG00000187741: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000187741

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/fanca.json